The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Published on Jun 1, 2020in The Lancet Gastroenterology & Hepatology12.856
· DOI :10.1016/S2468-1253(19)30408-X
M Ashworth Dirac1
Estimated H-index: 1
M Ashworth Dirac1
Estimated H-index: 1
+ 107 AuthorsFloriane Ausloos2
Estimated H-index: 2
Summary Background Gastro-oesophageal reflux disease is a common chronic ailment that causes uncomfortable symptoms and increases the risk of oesophageal adenocarcinoma. We aimed to report the burden of gastro-oesophageal reflux disease in 195 countries and territories between 1990 and 2017, using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017. Methods We did a systematic review to identify measurements of the prevalence of gastro-oesophageal reflux disease in geographically defined populations worldwide between 1990 and 2017. These estimates were analysed with DisMod-MR, a Bayesian mixed-effects meta-regression tool that incorporates predictive covariates and adjustments for differences in study design in a geographical cascade of models. Fitted values for broader geographical units inform prior distributions for finer geographical units. Prevalence was estimated for 195 countries and territories. Reports of the frequency and severity of symptoms among individuals with gastro-oesophageal reflux disease were used to estimate the prevalence of cases with no, mild to moderate, or severe to very severe symptoms at a given time; these estimates were multiplied by disability weights to estimate years lived with disability (YLD). Findings Data to estimate gastro-oesophageal reflux disease burden were scant, totalling 144 location-years (unique measurements from a year and location, regardless of whether a study reported them alongside measurements for other locations or years) of prevalence data. These came from six (86%) of seven GBD super-regions, 11 (52%) of 21 GBD regions, and 39 (20%) of 195 countries and territories. Mean estimates of age-standardised prevalence for all locations in 2017 ranged from 4408 cases per 100 000 population to 14 035 cases per 100 000 population. Age-standardised prevalence was highest (>11 000 cases per 100 000 population) in the USA, Italy, Greece, New Zealand, and several countries in Latin America and the Caribbean, north Africa and the Middle East, and eastern Europe; it was lowest ( Interpretation Gastro-oesophageal reflux disease is common worldwide, although less so in much of eastern Asia. The stability of our global age-standardised prevalence estimates over time suggests that the epidemiology of the disease has not changed, but the estimates of all-age prevalence and YLDs, which increased between 1990 and 2017, suggest that the burden of gastro-oesophageal reflux disease is nonetheless increasing as a result of ageing and population growth. Funding Bill & Melinda Gates Foundation.
  • References (55)
  • Citations (2)
📖 Papers frequently viewed together
13 Authors (Davies Adeloye, ..., Igor Rudan)
505 Citations
50 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Paul Moayyedi (Population Health Research Institute)H-Index: 3
#2John W. Eikelboom (Population Health Research Institute)H-Index: 93
Last. Salim Yusuf Mb Bs DPhil Frcpc (Population Health Research Institute)H-Index: 214
view all 50 authors...
Background & Aims Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies. We aimed to confirm these findings in an adequately powered randomized trial. Methods We performed a 3 × 2 partial factorial double-blind trial of 17,598 participants with stable cardiovascular disease and peripheral artery disease randomly assigned to groups given p...
9 CitationsSource
#1Chih-Hung Wang (NTU: National Taiwan University)H-Index: 13
#2Cheng-Han Li (NTU: National Taiwan University)H-Index: 1
Last. Chien-Chang Lee (Harvard University)H-Index: 28
view all 9 authors...
ABSTRACTObjective: We aimed to summarize the current evidence regarding the risk of pneumonia associated with proton pump inhibitors (PPI) treatment.Methods: We searched PubMed, Embase, and CENTRAL...
3 CitationsSource
The association between the long-term use of proton pump inhibitors (PPIs) and the risks of various diseases remains controversial. Therefore, the primary objective of this study was to quantify the associations as presented in the literature and to also provide this information to healthcare profes
6 CitationsSource
#1Gregory A. Roth (UW: University of Washington)H-Index: 52
#2Degu Abate (Haramaya University)H-Index: 3
Last. Christopher MargonoH-Index: 162
view all 1020 authors...
Summary Background Global development goals increasingly rely on country-specific estimates for benchmarking a nation's progress. To meet this need, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 estimated global, regional, national, and, for selected locations, subnational cause-specific mortality beginning in the year 1980. Here we report an update to that study, making use of newly available data and improved methods. GBD 2017 provides a comprehensive assessment of...
204 CitationsSource
#1Jeffrey D. Stanaway (UW: University of Washington)H-Index: 36
#2Ashkan Afshin (UW: University of Washington)H-Index: 33
Last. Christopher MargonoH-Index: 162
view all 1043 authors...
Summary Background The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 comparative risk assessment (CRA) is a comprehensive approach to risk factor quantification that offers a useful tool for synthesising evidence on risks and risk–outcome associations. With each annual GBD study, we update the GBD CRA to incorporate improved methods, new risks and risk–outcome pairs, and new data on risk exposure levels and risk–outcome associations. Methods We used the CRA framework dev...
191 CitationsSource
#1Christopher MargonoH-Index: 162
Last. Stephen S LimH-Index: 66
view all 988 authors...
Summary Background Population estimates underpin demographic and epidemiological research and are used to track progress on numerous international indicators of health and development. To date, internationally available estimates of population and fertility, although useful, have not been produced with transparent and replicable methods and do not use standardised estimates of mortality. We present single-calendar year and single-year of age estimates of fertility and population by sex with stan...
22 CitationsSource
#1Hmwe H KyuH-Index: 34
#2Degu AbateH-Index: 7
Last. Elisabete Vainio WeiderpassH-Index: 102
view all 50 authors...
115 CitationsSource
#1Gbd DiseaseH-Index: 1
#2Injury IncidenceH-Index: 1
Last. Giuseppe RemuzziH-Index: 152
view all 12 authors...
Research reported in this publication was supported by the Bill & Melinda Gates Foundation, the University of Melbourne, Public Health England, the Norwegian Institute of Public Health, St Jude Children’s Research Hospital, the National Institute on Ageing of the National Institutes of Health (award P30AG047845), and the National Institute of Mental Health of the National Institutes of Health (award R01MH110163).
239 CitationsSource
#1Daniel DickerH-Index: 28
#2Grant NguyenH-Index: 39
Last. Christopher MargonoH-Index: 162
view all 1159 authors...
Summary Background Assessments of age-specific mortality and life expectancy have been done by the UN Population Division, Department of Economics and Social Affairs (UNPOP), the United States Census Bureau, WHO, and as part of previous iterations of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD). Previous iterations of the GBD used population estimates from UNPOP, which were not derived in a way that was internally consistent with the estimates of the numbers of deaths in...
61 CitationsSource
#1Leonardo Henry Eusebi (UNIBO: University of Bologna)H-Index: 20
#2Raguprakash Ratnakumaran (University of Leeds)H-Index: 3
Last. Alexander C. Ford Mrcp (University of Leeds)H-Index: 59
view all 6 authors...
Objectives Gastro-oesophageal reflux symptoms are common in the community, but there has been no definitive systematic review and meta-analysis of data from all studies to estimate their global prevalence, or potential risk factors for them. Design Medline, Embase and Embase Classic were searched (until September 2016) to identify population-based studies that reported the prevalence of gastro-oesophageal reflux symptoms in adults (≥15 years); gastro-oesophageal reflux was defined using symptom-...
30 CitationsSource
Cited By2
#1Rami Sweis (UCLH: University College Hospital)H-Index: 15
#2Mark Fox (UZH: University of Zurich)H-Index: 38